BRIEF-Protalix Biotherapeutics updates on Phase II clinical trial results for Alidornase Alfa
June 7 Protalix Biotherapeutics Inc:
* Protalix biotherapeutics announces Phase II clinical trial results for Alidornase Alfa in cystic fibrosis presented at the 40th EUROPEAN cystic fibrosis society conference
* "Alidornase Alfa was well tolerated with no serious adverse events reported"
* Protalix Biotherapeutics Inc says clinical data demonstrate over 70% reduction in presence of pseudomonas Source text for Eikon: Further company coverage:
WORLD NEWS SCHEDULE AT 1800 GMT/2 PM ET
Iraqi forces free hundreds of civilians in Mosul Old City battles as death toll mounts
CEO of Raytheon's Forcepoint eyes IPO -Boersen-Zeitung
FRANKFURT, June 24 U.S. missile maker Raytheon's cybersecurity unit could thrive were it to be listed separately, the head of the unit, Forcepoint, told German business daily Boersenzeitung in an interview published on Saturday.